Cargando…

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

BACKGROUND: In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. OBJECTIVES: We examined clinically meaningful improvements in selected patient‐reported outcomes (PROs). METHODS: JADE COMPARE was a multicentre, phase 3 randomized, double‐blind,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thyssen, J.P., Yosipovitch, G., Paul, C., Kwatra, S.G., Chu, C.‐Y., DiBonaventura, M., Feeney, C., Zhang, F., Myers, D., Rojo, R., Valdez, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Allergy and Eczema
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300205/ https://www.ncbi.nlm.nih.gov/pubmed/34779063 http://dx.doi.org/10.1111/jdv.17813

Ejemplares similares

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
por: Ständer, Sonja, et al.
Publicado: (2022)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic dermatitis from the BREEZE‐AD7 Phase 3 randomized trial
por: Wollenberg, A., et al.
Publicado: (2021)

Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
por: Roekevisch, E., et al.
Publicado: (2020)

Validation of the Patient‐Oriented SCORing for Atopic Dermatitis tool for black skin
por: Faye, O., et al.
Publicado: (2019)

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

Both children and adult patients with difficult‐to‐treat atopic dermatitis have high prevalences of concomitant allergic contact dermatitis and are frequently polysensitized
por: Boonstra, M., et al.
Publicado: (2018)

The current extent of and need for shared decision making in atopic dermatitis and psoriasis in the Netherlands: an online survey study amongst patients and physicians
por: van der Kraaij, G.E., et al.
Publicado: (2020)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
por: Paller, A.S., et al.
Publicado: (2020)

Stepwise approach of development of dermo‐cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance
por: Ribet, V., et al.
Publicado: (2019)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Defining and measuring ‘eczema control’: an international qualitative study to explore the views of those living with and treating atopic eczema
por: Howells, L., et al.
Publicado: (2019)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Allergen‐specific immunotherapy with apples: selected cultivars could be a promising tool for birch pollen allergy
por: Nothegger, B., et al.
Publicado: (2020)

A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
por: Lapeere, H., et al.
Publicado: (2019)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Emollient efficacy and acceptability in the treatment of eczematous dry skin: A double-blind, randomised comparison of two UK-marketed products
por: Djokic-Gallagher, Jasmina, et al.
Publicado: (2016)

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents
por: Ständer, S., et al.
Publicado: (2022)

Relations between a standardized experimental stressor and cutaneous sensory function in patients with chronic pruritus and healthy controls: an experimental case–control study
por: Schneider, G., et al.
Publicado: (2018)

Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies
por: Kim, Brian S., et al.
Publicado: (2021)

Burden of chronic urticaria relative to psoriasis in five European countries
por: Balp, M.M., et al.
Publicado: (2017)

Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need
por: Pereira, M.P., et al.
Publicado: (2018)

Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review
por: Silverberg, J.I., et al.
Publicado: (2022)

Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis
por: Kwatra, Shawn G., et al.
Publicado: (2021)

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
por: Li, Ling, et al.
Publicado: (2023)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis
por: Silverberg, J.I., et al.
Publicado: (2021)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Proteomics Profiling to Distinguish DOCK8 Deficiency From Atopic Dermatitis
por: Jacob, Minnie, et al.
Publicado: (2021)

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
por: McAleer, Jeremy P.
Publicado: (2023)

Survey of topical exposure concerns for patients and caregivers dealing with atopic dermatitis
por: Ratley, Grace, et al.
Publicado: (2023)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lh3cqtnk127gguc1kk26qj4ajf